YM116
YM116 is an orally active and competitive CYP17A1 (17,20-lyase) inhibitor (Ki: 0.38 nM). YM116 reduces the synthesis of adrenal androgens by preferentially inhibiting C17-20 lyase activity. YM116 decreases the serum testosterone concentration, reduces dehydroepiandrosterone sulfate levels and decreases prostatic weights.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 183012-13-7
- Formule: C16H13N3
- Masse moléculaire:247.29
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
Chemical Information
-
CAS No. 183012-13-7
-
Masse moléculaire 247.29
-
Formule C16H13N3
-
SMILES
C1(NC2=C3C=CC=C2)=C3C=CC(CC4=CN=CN4)=C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Ideyama Y, et al. Novel nonsteroidal inhibitor of cytochrome P450(17alpha) (17alpha-hydroxylase/C17-20 lyase), YM116, decreased prostatic weights by reducing serum concentrations of testosterone and adrenal androgens in rats. Prostate. 1998 Sep 15;37(1):10-8. [Content Brief]
[2]. Ideyama Y, et al. YM116, 2-(1H-imidazol-4-ylmethyl)-9H-carbazole, decreases adrenal androgen synthesis by inhibiting C17-20 lyase activity in NCI-H295 human adrenocortical carcinoma cells. Jpn J Pharmacol. 1999 Feb;79(2):213-20. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)